Summary The effect of melphalan alone or combined with various schedules of misonidazole (MISO) has been tested on a murine fibrosarcoma. The tumoricidal effect has been determined using the growth delay assay. Large single doses (500-1000mg kg-1) of MISO enhanced the anti-tumour effect of melphalan, especially at high melphalan doses. This was accompanied by a drop in body and tumour temperature and an increase in the melphalan half-life. The MISO-induced hypothermia was prevented in one experiment by keeping the mice in an ambient temperature of 35°C for 3 h. This reduced the exposure to melphalan but did not diminish the cytotoxic effect of the drug combination.
Hypoxic cell radiosensitizers such as misonidazole (MISO) have been shown to enhance the cytoxicity of certain chemotherapeutic agents in a variety of mouse tumours (see reviews by McNally, 1982; Millar, 1982; Siemann, 1982) . The majority of the studies have been with single doses and most have shown that chemotherapeutic enhancement occurs after high doses of MISO which would, however, have no clinical relevance (McNally, 1982; Millar, 1982; Siemann, 1982) . These single dose studies are difficult to translate directly into clinical terms, because of the 10-fold difference between mouse and man in the half-life of MISO, particularly since the cytotoxic effect to MISO is reported to be a supralinear function of exposure time (Hall et al., 1978; Stratford & Adams, 1978) . A few murine studies have been reported in which the human pharmacokinetics with lower plasma levels of MISO have been simulated by multiple injection schedules in order to assess the possible role of chemosensitization by MISO in the clinic (Hirst & Brown, 1982; McNally et al., 1983; Twentyman & Workman, 1983) . Some of these studies have demonstrated significant chemosensitization, but it is not a universal finding.
In this paper we report a comparison of the response of a fibrosarcoma (SA FA) to melphalan given in combination with large single doses of MISO, or small but prolonged exposures. The effect of each drug on the pharmacokinetics of the other has been measured, together with the Correspondence: V.S. Randhawa. Received 21 June 1984; and in revised form 25 October 1984. influence of these two drugs on body and tumour temperature. In addition, the influence of MISO induced hypothermia has been investigated by maintaining some of the animals in a 35°C environment shortly after drug administration to prevent the hypothermia.
Materials and methods

Mice and tumours
The fibrosarcoma SA FA grown in WHT/Gy f BSVS mice has been used. This tumour arose spontaneously and was maintained by serial passage in the inbred strain of origin at the Gray Laboratory for many years. For the last 4 years the cells have been kept in liquid nitrogen and no more than ten transplants have been used before taking fresh cells from the frozen store. All experiments have been performed with Category 4 specific pathogen free mice.
Drugs
All drugs were freshly prepared on the day of the experiment. Melphalan was first dissolved in 0.5ml of acid alcohol (2% HCI in ethanol) and then further diluted with 9.5 ml of sterile saline immediately before administration (final pH2 Figure 1 shows growth delay data obtained using chronic administration of MISO over an 8 h period, with graded doses of melphalan being administered either halfway through (i.e. at 4 h) or at the end of the chronic MISO administration. This more closely simulates what might occur in man where low MISO doses would be given, but the longer biological half-life in humans would maintain the MISO levels for many hours. No significant sensitization was seen with either of the chronic dosage regimes, at any dose level (Table I) .
A similar experiment was performed with cyclophosphamide and the results were essentially the same (data not shown). A significant enhancement was seen with 1000mgkg-1 MISO at all cyclophosphamide doses ranging from 40-160 mg kg-1. However, no enhancement was seen at any dose level with an 8 h chronic MISO exposure, whether the cyclophosphamide was given in the middle or at the end of the chronic MISO schedule.
Temperature effects Several authors have reported changes in body temperatures after high doses of MISO and these could contribute to the observed effects on the tumour. We have therefore measured the temperatures of both the tumour and the body core for a period of 5-6 h after drug administration. The results are shown in Table I 38.0 + 0.5°C, but the tumour temperatures were always -3°C lower (35.2 + 0.2°C). Large single doses of MISO caused a temperature drop which was dose dependent and which persisted for at least 5 h in animals kept at normal room temperature (21°C). This hypothermia was apparent in both rectal and tumour measurements. They both fell by 3°C after 500 mg kg-1 and by -5°C after 1000mg kg -. In this way the initial difference in temperature between the tumour and the body core was maintained (Table I ). The addition of 10mgkg-1 melphalan did not alter this hypothermic response.
Maintaining the mice in a warm room at 35°C for 3h after administration of the drugs prevented the rectal temperature falling below 35.5°C, and the tumours were in the range 34-36°C. Even after 3 h, however, a prompt drop in body and tumour temperature resulted when the animals were returned to a 21°C environment. Again the presence of melphalan did not influence this MISO-induced hypothermia.
There was a decrease by -1°C in the rectal and tumour temperatures of mice given repeated MISO injections compared with those given an equivalent volume of saline using the same schedule. These temperature variations were small compared to Figure 2 . Mice from the same transplant were randomly allocated to the two temperature regimes. In the left hand panel the response of mice kept at room temperature is shown. The effect of MISO in this particular experiment is similar to that for the pooled data in Figure IA . The area enclosed by + s.e. on each point is reproduced ( Figure 2B) Figure  2B an increased effect of the drug combination was seen if the mice were kept at 35°C instead of at 21°C.
Pharmacokinetics
The effect of drug dose and body temperature on the pharmacokinetics of both drugs has been studied. Melphalan (10mgkg-1) has no effect on the pharmacokinetics of MISO (1000mg kg-1) at 21°C or 35°C (data not shown). Figure 3 shows Table I . Although an 8 h exposure in the warm room was used for the pharmacology this was subsequently found to be too toxic for the growth delay experiments; animals died within a week after giving both drugs and maintaining them for 8 h at 35°C. The AUC for MISO for mice maintained at 35"C in Table I may therefore be a slight overestimate. However, since the concentration had fallen to 10% of peak levels by 3 h this is unlikely to be a major source of error. The melphalan concentration was determined for both tumour and plasma in mice given melphalan (l0mgkg-1) or combined with MISO. The plasma melphalan half lives are shown in Table I . The tumour results are shown in Figure 4 for all the doseage regimes. The single doses of MISO prolonged the melphalan half life, but there was no influence on melphalan pharmacokinetics when low levels of MISO were maintained for 8 h. The tumour exposure to melphalan (i.e. area under the curve) is listed in Table I .
Discussion
These data demonstrate that the chemosensitizing effects of MISO which can be shown with large doses are lost if, in an attempt to mimic the likely pharmacokinetics in human tumours, the drug is given as a low-dose chronic exposure. No enhancement of melphalan (or cyclophosphamide) cytotoxicity was observed when it was given either halfway through or at the end of an 8 h chronic MISO administration. This is, of course, disappointing for the clinical application of MISO in chemotherapy.
The other published studies of MISO and melphalan combinations are summarised in Table  II , and a similar conclusion can be drawn from them. With large single doses a significant effect is CMelphalan given at the end of 8 h chronic administration. dMelphalan given halfway through the 8 h chronic administration. seen in every study: A threshold dose of 300-500mgkg-1 seems to be needed. Only two studies at doses of 500 mg kg-1 or below have demonstrated chemosensitization (Rose et al., 1980; Sheldon et al., 1982) and two other studies have shown no effect at 500mgkg-1 (Fu et al., 1981; Twentyman & Workman, 1982) . Far fewer studies have been published using chronic MISO with melphalan. In these, two different tumours have been used, and in each case one study shows an extra cytotoxicity with the combination whilst the other shows none. With the RIF-1 tumour the same assay was used in different laboratories, whereas with WH FIB two different assays used by the same workers led to opposite conclusions. These studies were all performed with MISO levels of V.S. RANDHAWA el al. l00 ig ml -in blood, which are similar to those in the present study and also to those likely to be achieved in the clinic. The evidence for an increased effectiveness of melphalan combined with prolonged low dose MISO is seen from Tables I  and II to be less than compelling.
As the MISO dose is increased above 200mgkg-1 the total exposure of tumour cells to the drug would change, partly because of the higher peak concentration and also due to the extension of the half-life seen at high MISO doses (Workman, 1980) . Several in vitro studies have indicated that hypoxic cytotoxicity is more dependent upon exposure time (T) than peak concentration (C) (Hall et al., 1978; Stratford & Adams, 1978) and has been correlated with a time squared expression i.e. cytotoxicity ocC x T2 (Hall et al., 1978) .
The present set of data allows us to analyse this for the four schedules which have been compared. In Figure 5 the additional delay resulting from MISO treatment (relative to give 10mg kg-1 melphalan alone) has been plotted as a function of the tumour exposure to MISO, calculated from C x T (panel A) or form C x T2 (panel B). The data for chronic exposures fall below the data for acute single doses in both panels but the discrepancy is even greater for the C x T2 calculation than for the simpler C x T If MISO cytotoxicity plays a role in chemosensitization then these in vivo results do not support the concept of cytotoxicity being a supralinear function of overall time. Rather they stipport the view that a critical threshold level is needed, regardless of exposure time, to achieve additional tumour cell kill.
Large MISO doses cause a drop in body and tumour temperature which may influence many physiological and biochemical parameters, including respiration and heart rate, blood flow to tumour and normal tissues and the rate of various biochemical processes. The hydrolysis of melphalan, and its interaction with DNA (alkylation), could also be influenced by the changes in temperature. Figure 4 and Table I demonstrate that changes in the rate of melphalan removal from the plasma and tumour occur with large single doses of MISO. The extended plasma half-life has been reported by Stephens et al. (1981) , Clutterbuck (1982) and Hinchliffe et al. (1983) , but tumour measurements have not previously been available. Since changes in melphalan pharmacokinetics occur with high MISO doses it is possible that the chemosensitization observed with melphalan and MISO can be explained by increased exposure of the tumour cells to melphalan.
In Figure 5C , the additional delay from the combined treatment has been plotted as a function of tumour exposure to melphalan (calculated as C x T). For the 21°C data alone, it could be argued that the changes in melphalan exposure to the tumour could explain the observed effect. However, when the mice are maintained at 35°C the extension of the melphalan T112 and hence the exposure dose are both reduced, yet the combined treatment is more effective than any of the others, whereas the effect of melphalan alone is unchanged ( Figure 2B ). It is likely that several competing processes are occurring and the overall balance between them under different conditions will determine the The effects with cyclophosphamide were very similar i.e. an increase in tumour growth delay after large single doses of MISO. All the factors mentioned above would apply to this result, but in addition the rate at which the cyclophosphamide is metabolised to its active form could also be influenced by changes in body temperature.
Sieman (1984) recently reviewed the field of electron affinic radiosensitizers when combined with a variety of chemotherapeutic agents. He concluded that no single unifying mechanisms for chemosensitization exists and that changes in drug pharmacokinetics, cellular SH levels and repair of DNA damage are all involved. He also concluded that, although a therapeutic gain has generally been seen for large sensitizer doses, the results with clinically achievable dose levels needed further evaluation.
The present results indicate that low dose chronic MISO administration is ineffective, in this fibrosarcoma when combined with melphalan or cyclophosphamide. The chemosensitization by large single doses does not appear to be an artefact of the hypothermia that accompanies it, but rather seems to indicate that a critical peak MISO concentration (>70igg-') must be achieved in the tumour ( Figure 3 and Table I ). This could be attained clinically with large infrequent MISO doses, but the number of doses would be limited by the cumulative toxicity. However, since chemotherapy is usually given as large infrequent doses over many months, the toxicity experience from repeated smallish dosing in radiotherapy studies 2-5 times a week over 6-8 weeks may be a pessimistic guide to the tolerable MISO dose if it were combined with chemotherapy.
